Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
317.8 SEK | -1.01% | -2.01% | -3.79% |
Sales 2024 * | 794M 72.2M | Sales 2025 * | 1.07B 97.72M | Capitalization | 10.11B 919M |
---|---|---|---|---|---|
Net income 2024 * | 70M 6.36M | Net income 2025 * | 158M 14.36M | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | 454M 41.23M | Net cash position 2025 * | 476M 43.28M | EV / Sales 2025 * | 8.96 x |
P/E ratio 2024 * |
154
x | P/E ratio 2025 * |
67.2
x | Employees | 160 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.13% |
Latest transcript on Xvivo Perfusion AB
1 day | -2.13% | ||
1 week | +0.63% | ||
Current month | +16.73% | ||
1 month | +16.52% | ||
3 months | -1.08% | ||
6 months | +38.96% | ||
Current year | -2.58% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 12-08-31 | |
Director of Finance/CFO | 39 | - | |
Chief Tech/Sci/R&D Officer | 57 | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Camilla Öberg
BRD | Director/Board Member | 60 | 16-04-30 |
Chairman | 65 | - | |
Lars Henrikson
BRD | Director/Board Member | 69 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 317 | -1.25% | 1 217 |
24-04-18 | 321 | -2.13% | 41,987 |
24-04-17 | 328 | +1.08% | 28,621 |
24-04-16 | 324.5 | -2.26% | 99,215 |
24-04-15 | 332 | +2.63% | 75,889 |
Delayed Quote Nasdaq Stockholm, April 18, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.58% | 926M | |
-4.36% | 183B | |
-3.87% | 105B | |
-4.38% | 67.36B | |
+8.23% | 51.77B | |
+15.54% | 47.29B | |
-1.73% | 40.2B | |
+7.16% | 27.62B | |
-12.48% | 21.75B | |
-1.68% | 25.51B |
- Stock Market
- Equities
- XVIVO Stock